At the news
? BULLISHIMPACT 5/10 8-K filed Nov 13, 2026 at 08:35 ET
Tandem Diabetes Care received FDA 510(k) clearance for a tubeless cartridge and infusion set for its Tandem Mobi insulin pump, enabling up to 7 days of wear. Commercial launch is planned for the first half of 2027 in the U.S. This expands the product's addressable market by offering a tubeless option alongside the existing tubed configuration.
- Received FDA 510(k) clearance for Tandem Mobi tubeless cartridge and infusion set on November 12, 2026.
- Tubeless infusion set cleared for up to 7 days of wear; cartridge cleared for 3 days of use.
- Full commercial launch planned for first half of 2027 in the United States.
- Tandem Mobi pump is now cleared for both tubeless and tubed infusion options.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access